HIV/AIDS Therapy
U.S. FDA approves new anti-HIV protease inhibitor for use in combination therapy
Published in Medical Letter on the CDC and FDA, July 31st, 2005
Accelerated approval is a regulatory process that expedites the approval of therapies for serious or life-threatening illnesses that provide meaningful benefit to patients over existing treatments. This approval is based on 24-week data from ongoing studies. Longer term data will be needed before FDA can consider traditional approval for Aptivus. There are no study results demonstrating the effect of Aptivus on clinical progression of HIV-1.
The approved dose of Aptivus is 500 mg...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- HIV/AIDS Vaccine
Peptide capable of generating HIV-neutralizing activity identified - Male Infertility
Serine/threonine protein kinase needed for male fertility characterized - Measles Vaccine
Ability of measles protein to regulate genome replication examined - Measles Vaccine
Measles control is possible in areas of widespread HIV infection - Outbreaks
Coccidioidomycosis epidemic associated with climatic changes - Acintobacter Baumannii
A. baumannii outbreak caused by bla(OXA-21) determinant - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
